Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,totalStockholderEquity,intangibleAssets,capitalSurplus,totalLiab,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,SNW.DE,6308000000.0,1250749952,1266000000,,1982000000,,1566000000,2194000000,6202000000,2252000000,2252000000,101000000,-99000000,,,,404000000,8886000000,6634000000,2684000000,-270000000,,1578000000,1566000000,63001000000.0,,,,,,,,,,,,,,,,,,,,,,,,,,0,,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,SANOFI SA INHABER  EO 2,False,False,GER,88.75,1630574364,0.51000214,88.24,88.86,88.17,2470,REGULAR,0,2,0.57797164,88.17 - 88.86,88.24,88.63,88.7,2000,2000,finmb_687130,Sanofi,XETRA,EUR,8098,3301,13.82,0.18443881,74.93 - 91.17,-2.4199982,-0.0265438,74.93,91.17,3.2,9.167441,0.036264732,9.681,5.76,50.373,87.60886,1.1411438,0.013025438,85.259575,3.490425,0.040938806,111067070464,15.407986,1.7618566,15,Europe/Berlin,CEST,7200000,0.4,,,91.17,74.93,87.61,85.26,8.1k,3.3k,1.25B,,1.11B,11.18%,49.63%,,,,,,3.2,3.65%,3.20,3.63%,3.87,32.55%,,"May 05, 2021",,,"Dec 31, 2020","Mar 31, 2021",33.02%,21.10%,,20.01%,36.94B,29.48,-4.60%,25.27B,10.58B,12.2B,9.68,-7.00%,14.81B,11.86,23.68B,37.49,,50.37,,,Value,75008,Healthcare,99412,6,3,"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",Paris,33 1 53 77 40 00,4,1609372800,1622505600,4,France,http://www.sanofi.com,86400,5,"54, Rue La BoEtie",33 1 53 77 43 03,Drug Manufacturers—General
t-1,SNW.DE,6308000000.0,1250749952,1516000000,,1419000000,146000000.0,1081000000,2660000000,6351000000,1378000000,1378000000,403000000,-179000000,,,,329000000,9736000000,8358000000,3385000000,41000000,,1090000000,1081000000,63001000000.0,12329000000.0,362000000.0,51382000000.0,6092000000.0,8597000000.0,114529000000.0,2518000000.0,141000000.0,11426000000.0,44364000000.0,60121000000.0,11358000000.0,13915000000.0,19280000000.0,4212000000.0,2482000000.0,60826000000.0,10563000000.0,33786000000.0,2129000000.0,900000000.0,9953000000.0,19745000000.0,8352000000.0,5295000000.0,0,14506000000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,SANOFI SA INHABER  EO 2,False,False,GER,88.75,1630574364,0.51000214,88.24,88.86,88.17,2470,REGULAR,0,2,0.57797164,88.17 - 88.86,88.24,88.63,88.7,2000,2000,finmb_687130,Sanofi,XETRA,EUR,8098,3301,13.82,0.18443881,74.93 - 91.17,-2.4199982,-0.0265438,74.93,91.17,3.2,9.167441,0.036264732,9.681,5.76,50.373,87.60886,1.1411438,0.013025438,85.259575,3.490425,0.040938806,111067070464,15.407986,1.7618566,15,Europe/Berlin,CEST,7200000,0.4,,,91.17,74.93,87.61,85.26,8.1k,3.3k,1.25B,,1.11B,11.18%,49.63%,,,,,,3.2,3.65%,3.20,3.63%,3.87,32.55%,,"May 05, 2021",,,"Dec 31, 2020","Mar 31, 2021",33.02%,21.10%,,20.01%,36.94B,29.48,-4.60%,25.27B,10.58B,12.2B,9.68,-7.00%,14.81B,11.86,23.68B,37.49,,50.37,,,Value,75008,Healthcare,99412,6,3,"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",Paris,33 1 53 77 40 00,4,1609372800,1622505600,4,France,http://www.sanofi.com,86400,5,"54, Rue La BoEtie",33 1 53 77 43 03,Drug Manufacturers—General
t-2,SNW.DE,4514000000.0,1250749952,1321000000,,2449000000,146000000.0,1952000000,2182000000,6703000000,2614000000,2614000000,182000000,-91000000,,,,490000000,9879000000,7265000000,3176000000,-165000000,,1959000000,1952000000,63304000000.0,,,,,,,,,,,,,,,,,,,,,,,,,,0,,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,SANOFI SA INHABER  EO 2,False,False,GER,88.75,1630574364,0.51000214,88.24,88.86,88.17,2470,REGULAR,0,2,0.57797164,88.17 - 88.86,88.24,88.63,88.7,2000,2000,finmb_687130,Sanofi,XETRA,EUR,8098,3301,13.82,0.18443881,74.93 - 91.17,-2.4199982,-0.0265438,74.93,91.17,3.2,9.167441,0.036264732,9.681,5.76,50.373,87.60886,1.1411438,0.013025438,85.259575,3.490425,0.040938806,111067070464,15.407986,1.7618566,15,Europe/Berlin,CEST,7200000,0.4,,,91.17,74.93,87.61,85.26,8.1k,3.3k,1.25B,,1.11B,11.18%,49.63%,,,,,,3.2,3.65%,3.20,3.63%,3.87,32.55%,,"May 05, 2021",,,"Dec 31, 2020","Mar 31, 2021",33.02%,21.10%,,20.01%,36.94B,29.48,-4.60%,25.27B,10.58B,12.2B,9.68,-7.00%,14.81B,11.86,23.68B,37.49,,50.37,,,Value,75008,Healthcare,99412,6,3,"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",Paris,33 1 53 77 40 00,4,1609372800,1622505600,4,France,http://www.sanofi.com,86400,5,"54, Rue La BoEtie",33 1 53 77 43 03,Drug Manufacturers—General
t-3,SNW.DE,4514000000.0,1250749952,1352000000,,8166000000,182000000.0,7598000000,2297000000,5796000000,1409000000,1409000000,312000000,-145000000,,,,560000000,8438000000,7029000000,2642000000,6757000000,,7606000000,7598000000,63304000000.0,13536000000.0,181000000.0,52333000000.0,3485000000.0,10311000000.0,115819000000.0,2512000000.0,2816000000.0,12174000000.0,45254000000.0,60611000000.0,9223000000.0,15969000000.0,18808000000.0,4830000000.0,3022000000.0,60855000000.0,10604000000.0,34883000000.0,2319000000.0,,7203000000.0,20404000000.0,8895000000.0,4920000000.0,0,16075000000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,SANOFI SA INHABER  EO 2,False,False,GER,88.75,1630574364,0.51000214,88.24,88.86,88.17,2470,REGULAR,0,2,0.57797164,88.17 - 88.86,88.24,88.63,88.7,2000,2000,finmb_687130,Sanofi,XETRA,EUR,8098,3301,13.82,0.18443881,74.93 - 91.17,-2.4199982,-0.0265438,74.93,91.17,3.2,9.167441,0.036264732,9.681,5.76,50.373,87.60886,1.1411438,0.013025438,85.259575,3.490425,0.040938806,111067070464,15.407986,1.7618566,15,Europe/Berlin,CEST,7200000,0.4,,,91.17,74.93,87.61,85.26,8.1k,3.3k,1.25B,,1.11B,11.18%,49.63%,,,,,,3.2,3.65%,3.20,3.63%,3.87,32.55%,,"May 05, 2021",,,"Dec 31, 2020","Mar 31, 2021",33.02%,21.10%,,20.01%,36.94B,29.48,-4.60%,25.27B,10.58B,12.2B,9.68,-7.00%,14.81B,11.86,23.68B,37.49,,50.37,,,Value,75008,Healthcare,99412,6,3,"Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",Paris,33 1 53 77 40 00,4,1609372800,1622505600,4,France,http://www.sanofi.com,86400,5,"54, Rue La BoEtie",33 1 53 77 43 03,Drug Manufacturers—General
